For over four years, OncoSec (ONCS) has been a somewhat ignored and under-appreciated stepchild in the immuno-oncology world, but that is about to change. Born of a technology license from DNA vaccine company Inovio, which has achieved a $564 million market capitalization based on the same electroporation technology as was licensed to OncoSec in other diseases, OncoSec has plodded along with various changes in therapeutic strategy, management turnover in key scientific positions, a reverse stock split that is still cannon fodder on message boards, a young CEO who has been the target of a largely retail shareholder base's ire, and a months-long delay in starting an important combination trial with anti-PD1 agent Keytruda.

However, as discussed in detail below, the tide is turning for OncoSec as all of these overhangs are either currently, or are on the verge of being resolved, and the next six to nine months should prove the value of the Company's technology in many ways, including a near-term update of efficacy in a second tumor type (Merkel cell cancer). In last week's biotech sell-off, many high-fliers went from being very expensive to just being expensive, reversing big gains generated over just the previous 1-3 months, but OncoSec started the week as cheap and ended it ridiculously so.

With many of its biotech peers still not sufficiently undervalued to warrant purchase, OncoSec finds itself on sale (a paltry $44 million enterprise value) with a clear therapeutic focus, a star Chief Scientific Officer and Chief Medical Officer steering development strategy (neither of whom has had much exposure to investors), two large biotech funds as new investors, a $700 million deal between AstraZeneca and Inovio that validates electroporation of IL-12 as an immunotherapy approach, and a development partnership possible much sooner than anticipated. After a brief company description and a recap of data generated to date, presented below are ten reasons to buy OncoSec.

All statements and opinions expressed herein are those of
the editors and staff of Avenaddy, Inc. and are subject to change without
notice. The Newsletter maintains editorial control over its publications
and the companies profiled therein do not have any editorial rights
concerning the information published about them. No information contained
in our website, e-mail communications or our publications should be
considered as a solicitation to purchase or sell any of the securities
mentioned. Avenaddy Inc, its principals or employees are not registered
investment advisors or a registered securities broker dealer. We do not
undertake or represent to make investment recommendations or to give
advice pertaining to the purchase or sale of the securities mentioned in
our web site, e-mail communications or publications. While we believe all
sources of information provided by us and contained in our publication to
be accurate and reliable, we cannot and do not guarantee the accuracy of
information we received from third parties. Readers are encouraged to do
their own due diligence before investing in any securities mentioned in
this newsletter. Investing in securities is speculative and carries a
high degree of risk. We encourage our readers to invest carefully and read
the investor information available at the web sites of the Securities and
Exchange Commission at http://www.sec.gov and/or the National
Association of Securities Dealers at http://www.finra.org. We also recommend that
you read the SEC advisory to investors concerning Internet Stock Fraud,
which can be found at http://www.sec.gov/consumer/cyberfr.htm. Readers can review all
public filings by companies at the SEC's EDGAR page. The Avenaddy
Newsletter is an electronic publication committed to providing our
readers with useful information on publicly traded companies. The
newsletter sometimes contracts with third parties or publicly traded
companies and receives compensation from them in the form of cash and
sometimes restricted securities as payment for publishing information and
opinion about the company and the trading market for their securities.
Principals of the newsletter may also purchase or sell securities of the
companies in the open market from time to time. Avenaddy, Inc. in
conjunction with Mobius Bio has received compensation of five thousand
dollars cash from OncoSec for the distribution of this newsletter, and
should be considered in making an investment decision regarding companies
mentioned in this newsletter. The information found in this newsletter is
protected by the copyright laws of the United States and may not be
copied, or reproduced in any way without the expressed, written consent
of Avenaddy, Inc.